First Header Logo Second Header Logo

Connection

Patricia Gallagher to Peptide Fragments

Back to Details
This is a "connection" page, showing publications Patricia Gallagher has written about Peptide Fragments.
Patricia Gallagher
Connection Strength
4.416
Peptide Fragments
  1. Rahimi O, Kirby J, Varagic J, Westwood B, Tallant EA, Gallagher PE. Angiotensin-(1-7) reduces doxorubicin-induced cardiac dysfunction in male and female Sprague-Dawley rats through antioxidant mechanisms. . 2020 04 01; 318(4):H883-H894.
    View in: PubMed
    Score: 0.569
  2. Gallagher PE, Arter AL, Deng G, Tallant EA. Angiotensin-(1-7): a peptide hormone with anti-cancer activity. Curr Med Chem. 2014; 21(21):2417-23.
    View in: PubMed
    Score: 0.372
  3. Krishnan B, Smith TL, Dubey P, Zapadka ME, Torti FM, Willingham MC, Tallant EA, Gallagher PE. Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis. Prostate. 2013 Jan; 73(1):71-82.
    View in: PubMed
    Score: 0.333
  4. Cook KL, Metheny-Barlow LJ, Tallant EA, Gallagher PE. Angiotensin-(1-7) reduces fibrosis in orthotopic breast tumors. Cancer Res. 2010 Nov 01; 70(21):8319-28.
    View in: PubMed
    Score: 0.296
  5. Gallagher PE, Ferrario CM, Tallant EA. MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides. . 2008 Nov; 295(5):C1169-74.
    View in: PubMed
    Score: 0.257
  6. Menon J, Soto-Pantoja DR, Callahan MF, Cline JM, Ferrario CM, Tallant EA, Gallagher PE. Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Res. 2007 Mar 15; 67(6):2809-15.
    View in: PubMed
    Score: 0.232
  7. Gallagher PE, Chappell MC, Ferrario CM, Tallant EA. Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes. . 2006 Feb; 290(2):C420-6.
    View in: PubMed
    Score: 0.209
  8. Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. . 2005 Oct; 289(4):H1560-6.
    View in: PubMed
    Score: 0.205
  9. Gallagher PE, Tallant EA. Inhibition of human lung cancer cell growth by angiotensin-(1-7). Carcinogenesis. 2004 Nov; 25(11):2045-52.
    View in: PubMed
    Score: 0.193
  10. Wester A, Devocelle M, Tallant EA, Chappell MC, Gallagher PE, Paradisi F. Stabilization of Angiotensin-(1-7) by key substitution with a cyclic non-natural amino acid. Amino Acids. 2017 10; 49(10):1733-1742.
    View in: PubMed
    Score: 0.119
  11. Willey JS, Bracey DN, Gallagher PE, Tallant EA, Wiggins WF, Callahan MF, Smith TL, Emory CL. Angiotensin-(1-7) Attenuates Skeletal Muscle Fibrosis and Stiffening in a Mouse Model of Extremity Sarcoma Radiation Therapy. J Bone Joint Surg Am. 2016 Jan 06; 98(1):48-55.
    View in: PubMed
    Score: 0.107
  12. Brosnihan KB, Pulgar VM, Gallagher PE, Neves LA, Yamaleyeva LM. Local uterine Ang-(1-7) infusion augments the expression of cannabinoid receptors and differentially alters endocannabinoid metabolizing enzymes in the decidualized uterus of pseudopregnant rats. Reprod Biol Endocrinol. 2015 Jan 17; 13:5.
    View in: PubMed
    Score: 0.100
  13. Carver KA, Smith TL, Gallagher PE, Tallant EA. Angiotensin-(1-7) prevents angiotensin II-induced fibrosis in cremaster microvessels. Microcirculation. 2015 Jan; 22(1):19-27.
    View in: PubMed
    Score: 0.100
  14. Moore ED, Kooshki M, Metheny-Barlow LJ, Gallagher PE, Robbins ME. Angiotensin-(1-7) prevents radiation-induced inflammation in rat primary astrocytes through regulation of MAP kinase signaling. Free Radic Biol Med. 2013 Dec; 65:1060-1068.
    View in: PubMed
    Score: 0.091
  15. Garcia-Espinosa MA, Shaltout HA, Gallagher PE, Chappell MC, Diz DI. In vivo expression of angiotensin-(1-7) lowers blood pressure and improves baroreflex function in transgenic (mRen2)27 rats. J Cardiovasc Pharmacol. 2012 Aug; 60(2):150-7.
    View in: PubMed
    Score: 0.084
  16. Krishnan B, Torti FM, Gallagher PE, Tallant EA. Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1. Prostate. 2013 Jan; 73(1):60-70.
    View in: PubMed
    Score: 0.083
  17. McCollum LT, Gallagher PE, Tallant EA. Angiotensin-(1-7) abrogates mitogen-stimulated proliferation of cardiac fibroblasts. Peptides. 2012 Apr; 34(2):380-8.
    View in: PubMed
    Score: 0.081
  18. McCollum LT, Gallagher PE, Ann Tallant E. Angiotensin-(1-7) attenuates angiotensin II-induced cardiac remodeling associated with upregulation of dual-specificity phosphatase 1. . 2012 Feb 01; 302(3):H801-10.
    View in: PubMed
    Score: 0.080
  19. Gallagher PE, Cook K, Soto-Pantoja D, Menon J, Tallant EA. Angiotensin peptides and lung cancer. Curr Cancer Drug Targets. 2011 May; 11(4):394-404.
    View in: PubMed
    Score: 0.077
  20. Varagic J, Ahmad S, Brosnihan KB, Groban L, Chappell MC, Tallant EA, Gallagher PE, Ferrario CM. Decreased cardiac Ang-(1-7) is associated with salt-induced cardiac remodeling and dysfunction. Ther Adv Cardiovasc Dis. 2010 Feb; 4(1):17-25.
    View in: PubMed
    Score: 0.070
  21. Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM. Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin Cancer Res. 2009 Dec 01; 15(23):7398-404.
    View in: PubMed
    Score: 0.070
  22. Soto-Pantoja DR, Menon J, Gallagher PE, Tallant EA. Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. . 2009 Jun; 8(6):1676-83.
    View in: PubMed
    Score: 0.068
  23. Gallagher PE, Ferrario CM, Tallant EA. Regulation of ACE2 in cardiac myocytes and fibroblasts. . 2008 Dec; 295(6):H2373-9.
    View in: PubMed
    Score: 0.065
  24. Diz DI, Garcia-Espinosa MA, Gallagher PE, Ganten D, Ferrario CM, Averill DB. Angiotensin-(1-7) and baroreflex function in nucleus tractus solitarii of (mRen2)27 transgenic rats. J Cardiovasc Pharmacol. 2008 Jun; 51(6):542-8.
    View in: PubMed
    Score: 0.063
  25. Anton L, Merrill DC, Neves LA, Stovall K, Gallagher PE, Diz DI, Moorefield C, Gruver C, Ferrario CM, Brosnihan KB. Activation of local chorionic villi angiotensin II levels but not angiotensin (1-7) in preeclampsia. Hypertension. 2008 Apr; 51(4):1066-72.
    View in: PubMed
    Score: 0.062
  26. Neves LA, Stovall K, Joyner J, Valdés G, Gallagher PE, Ferrario CM, Merrill DC, Brosnihan KB. ACE2 and ANG-(1-7) in the rat uterus during early and late gestation. . 2008 Jan; 294(1):R151-61.
    View in: PubMed
    Score: 0.061
  27. Ferrario CM, Jessup J, Gallagher PE, Averill DB, Brosnihan KB, Ann Tallant E, Smith RD, Chappell MC. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int. 2005 Nov; 68(5):2189-96.
    View in: PubMed
    Score: 0.053
  28. Sakima A, Averill DB, Gallagher PE, Kasper SO, Tommasi EN, Ferrario CM, Diz DI. Impaired heart rate baroreflex in older rats: role of endogenous angiotensin-(1-7) at the nucleus tractus solitarii. Hypertension. 2005 Aug; 46(2):333-40.
    View in: PubMed
    Score: 0.052
  29. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005 May 24; 111(20):2605-10.
    View in: PubMed
    Score: 0.051
  30. Igase M, Strawn WB, Gallagher PE, Geary RL, Ferrario CM. Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. . 2005 Sep; 289(3):H1013-9.
    View in: PubMed
    Score: 0.051
  31. Modrall JG, Sadjadi J, Brosnihan KB, Gallagher PE, Yu CH, Kramer GL, Bernstein KE, Chappell MC. Depletion of tissue angiotensin-converting enzyme differentially influences the intrarenal and urinary expression of angiotensin peptides. Hypertension. 2004 Apr; 43(4):849-53.
    View in: PubMed
    Score: 0.047
  32. Yamaleyeva LM, Neves LA, Coveleskie K, Diz DI, Gallagher PE, Brosnihan KB. AT1, AT2, and AT(1-7) receptor expression in the uteroplacental unit of normotensive and hypertensive rats during early and late pregnancy. Placenta. 2013 Jun; 34(6):497-502.
    View in: PubMed
    Score: 0.022
  33. Nautiyal M, Katakam PV, Busija DW, Gallagher PE, Tallant EA, Chappell MC, Diz DI. Differences in oxidative stress status and expression of MKP-1 in dorsal medulla of transgenic rats with altered brain renin-angiotensin system. . 2012 Oct 15; 303(8):R799-806.
    View in: PubMed
    Score: 0.021
  34. Trask AJ, Groban L, Westwood BM, Varagic J, Ganten D, Gallagher PE, Chappell MC, Ferrario CM. Inhibition of angiotensin-converting enzyme 2 exacerbates cardiac hypertrophy and fibrosis in Ren-2 hypertensive rats. Am J Hypertens. 2010 Jun; 23(6):687-93.
    View in: PubMed
    Score: 0.018
  35. Anton L, Merrill DC, Neves LA, Diz DI, Corthorn J, Valdes G, Stovall K, Gallagher PE, Moorefield C, Gruver C, Brosnihan KB. The uterine placental bed Renin-Angiotensin system in normal and preeclamptic pregnancy. Endocrinology. 2009 Sep; 150(9):4316-25.
    View in: PubMed
    Score: 0.017
  36. Yamaleyeva LM, Pendergrass KD, Pirro NT, Gallagher PE, Groban L, Chappell MC. Ovariectomy is protective against renal injury in the high-salt-fed older mRen2. Lewis rat. . 2007 Oct; 293(4):H2064-71.
    View in: PubMed
    Score: 0.015
  37. Jessup JA, Gallagher PE, Averill DB, Brosnihan KB, Tallant EA, Chappell MC, Ferrario CM. Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. . 2006 Nov; 291(5):H2166-72.
    View in: PubMed
    Score: 0.014
  38. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004 May; 43(5):970-6.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.